BioTuesdays: Oramed sees value creating events through 2016

Josh Hexter, Oramed’s COO, spoke with about Oramed’s progress and future advances. “Our ORMD-0801 drug candidate has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications”

Join our mailing list

Skip to content